| Full Name | Myeyedr. |
|---|---|
| Type | Facility |
| Speciality | Optometrist |
| Location | 145 Wakelee Ave, Ansonia, Connecticut |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396119194 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | (* (Not Available)) | Primary |
| Provider Name | Peter A Silver |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1659323210 PECOS PAC ID: 2769451442 Enrollment ID: I20040929000656 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Michelene Todd |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1962400416 PECOS PAC ID: 0446219794 Enrollment ID: I20041004000707 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Andrew Stack |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1306983648 PECOS PAC ID: 5597716803 Enrollment ID: I20050203000701 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Patricia A Youngquist |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1972650430 PECOS PAC ID: 2062454580 Enrollment ID: I20050525000488 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Catherine M Ferentini |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1144297425 PECOS PAC ID: 9133138936 Enrollment ID: I20060405000699 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Thuylinh Roschanagar |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1487604617 PECOS PAC ID: 9133130636 Enrollment ID: I20060516000058 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Christine Kantor |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1235145764 PECOS PAC ID: 6103821921 Enrollment ID: I20060928000380 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Rachel L Hawran |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1528084662 PECOS PAC ID: 9537166772 Enrollment ID: I20061031000206 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Monique L Dawson |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1902835713 PECOS PAC ID: 5496756264 Enrollment ID: I20070122000272 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Susan Evans |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1629106729 PECOS PAC ID: 4284739855 Enrollment ID: I20070411000051 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Sharon Martino |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1790740371 PECOS PAC ID: 9032107131 Enrollment ID: I20070721000026 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Dean R Harvey |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1558451989 PECOS PAC ID: 7911077219 Enrollment ID: I20080529000247 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Wendy P Kok |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1376709303 PECOS PAC ID: 8123187663 Enrollment ID: I20081112000630 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Dennis P Iadarola |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1649251562 PECOS PAC ID: 2264592922 Enrollment ID: I20081125000623 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Scott E Saunders |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1538149570 PECOS PAC ID: 1850453499 Enrollment ID: I20081216000532 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Sean Christopher Mcloughlin |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1457407835 PECOS PAC ID: 1254496334 Enrollment ID: I20090225000084 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Laura A Mafuz |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1447273719 PECOS PAC ID: 8729133343 Enrollment ID: I20090903000557 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Kevin So |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1710110390 PECOS PAC ID: 1254477847 Enrollment ID: I20091013000381 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Melvyn S Mazer |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1861470569 PECOS PAC ID: 9032254875 Enrollment ID: I20100304000856 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Shannon M Mulligan |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1528018157 PECOS PAC ID: 1052448966 Enrollment ID: I20100426000260 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Peter Remillard |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1063462174 PECOS PAC ID: 1759418668 Enrollment ID: I20100426000293 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Mark G Ryan |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1548211220 PECOS PAC ID: 8820125735 Enrollment ID: I20100426000315 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Joseph J Carillo |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1932162351 PECOS PAC ID: 5698802510 Enrollment ID: I20100426000389 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Mara S Capuano |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1750343711 PECOS PAC ID: 4486781309 Enrollment ID: I20100427000001 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Laura C Dake-roche |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1558323428 PECOS PAC ID: 5395872212 Enrollment ID: I20100427000002 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Janine R Elder |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1942264049 PECOS PAC ID: 6204963127 Enrollment ID: I20100427000004 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Louis J Rodier |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1801846084 PECOS PAC ID: 7810024734 Enrollment ID: I20100427000031 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | John E Stanley |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1922050285 PECOS PAC ID: 5991832818 Enrollment ID: I20100427000057 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Raymond T Szczepanski |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1912011487 PECOS PAC ID: 1557492568 Enrollment ID: I20100708000035 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Marcie Lustgarten |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1134190887 PECOS PAC ID: 1557493111 Enrollment ID: I20100716000441 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Helen Newton |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1568567394 PECOS PAC ID: 4880726066 Enrollment ID: I20100723000505 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Mark David Sturgis |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1740226752 PECOS PAC ID: 6305855776 Enrollment ID: I20100927001014 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Megan Young |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1144533910 PECOS PAC ID: 1951596170 Enrollment ID: I20101115000048 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Judith Elson |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1043267537 PECOS PAC ID: 9739377391 Enrollment ID: I20101223000041 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Richard J Colo |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1538259767 PECOS PAC ID: 6901087659 Enrollment ID: I20110301000169 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Michael J Aucello |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1457395337 PECOS PAC ID: 8022295153 Enrollment ID: I20110526000728 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Patricia A Aucello |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1417902289 PECOS PAC ID: 8628961422 Enrollment ID: I20110603000279 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Sheri M Sparks |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1417265372 PECOS PAC ID: 8426235813 Enrollment ID: I20110613000467 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Kathryn H Bony |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1013997923 PECOS PAC ID: 4981659679 Enrollment ID: I20110627000385 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Louis G Hochberg |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1851315170 PECOS PAC ID: 3173798444 Enrollment ID: I20111215000032 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Joel Roffer |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1902946957 PECOS PAC ID: 1759558554 Enrollment ID: I20120119000259 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | William J Filchak |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1962584383 PECOS PAC ID: 5597923847 Enrollment ID: I20120216000323 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Nicholas Motto |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1861586562 PECOS PAC ID: 9931008604 Enrollment ID: I20120229000463 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Jane Khorosh |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1942581145 PECOS PAC ID: 4880853597 Enrollment ID: I20120315000074 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Marc F Denigris |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1487879656 PECOS PAC ID: 7113181710 Enrollment ID: I20120612000081 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Stephen M Dincher |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1750679346 PECOS PAC ID: 1254580640 Enrollment ID: I20120928000164 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Kelly T Nguyen |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1366757932 PECOS PAC ID: 3173719085 Enrollment ID: I20130805000236 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Barbara A Dune |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1255644811 PECOS PAC ID: 2961638366 Enrollment ID: I20131113000482 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Austin M White |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1528012333 PECOS PAC ID: 2163595141 Enrollment ID: I20140827000101 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Gregory J Nigrelli |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1891195830 PECOS PAC ID: 7618291063 Enrollment ID: I20150114000038 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Sidet Sou |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1285818724 PECOS PAC ID: 8325355795 Enrollment ID: I20150917000194 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Stephanie L Sturgis |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1083098156 PECOS PAC ID: 8022326131 Enrollment ID: I20151008002245 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Matthew Paul Steciak |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1952781510 PECOS PAC ID: 1254634249 Enrollment ID: I20160126000744 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Reshma Patel |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1629452420 PECOS PAC ID: 5597069302 Enrollment ID: I20160215001066 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Anuradha Veerappan |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1992069272 PECOS PAC ID: 3577851674 Enrollment ID: I20161005001010 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Harvard Sylvan |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1578910816 PECOS PAC ID: 6406144393 Enrollment ID: I20161010000286 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Rishi Patel |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1831634393 PECOS PAC ID: 2668740069 Enrollment ID: I20170607001584 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Fatin Saleh |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1922556786 PECOS PAC ID: 6608148291 Enrollment ID: I20170816003096 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Amanda A Khalil |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1659808707 PECOS PAC ID: 0749554970 Enrollment ID: I20170926003899 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Jamee Patel |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1073934428 PECOS PAC ID: 7012283625 Enrollment ID: I20171026002253 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Xiuyang Guo |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1285145508 PECOS PAC ID: 7911263785 Enrollment ID: I20171110000675 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Alisha Martin |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1912430745 PECOS PAC ID: 3173882388 Enrollment ID: I20180116002079 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Hongping Xu |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1528574415 PECOS PAC ID: 5193086262 Enrollment ID: I20180306002054 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Stephanie T Sullivan |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1942720826 PECOS PAC ID: 1456615434 Enrollment ID: I20180426002660 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Deepak Sharma |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1164942546 PECOS PAC ID: 5193074821 Enrollment ID: I20180814001338 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Kimberly Bridget Raucci |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1578030458 PECOS PAC ID: 3173867744 Enrollment ID: I20181208000035 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Tiffany Nicole Deleon |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1760969133 PECOS PAC ID: 9133460298 Enrollment ID: I20190418000550 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Roderick Lucien Swift |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1467947812 PECOS PAC ID: 6305196320 Enrollment ID: I20190625001289 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Jennifer Wagh |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1417443417 PECOS PAC ID: 3476800467 Enrollment ID: I20190910002796 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Ryan Grand |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1790277333 PECOS PAC ID: 0042540619 Enrollment ID: I20190924002995 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Stacey Flynt |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1639661085 PECOS PAC ID: 0749530962 Enrollment ID: I20191004002417 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Amara Akbar |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1558918144 PECOS PAC ID: 9234460197 Enrollment ID: I20191008002829 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Rita Nieu |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1952965972 PECOS PAC ID: 6507197969 Enrollment ID: I20191016001231 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Tony Tran |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1487212346 PECOS PAC ID: 5597092130 Enrollment ID: I20191111001650 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Nguyen Tran |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1083259428 PECOS PAC ID: 3971939281 Enrollment ID: I20200205001502 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Brittany Strebig |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1396388179 PECOS PAC ID: 4880021195 Enrollment ID: I20200226002856 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Sadia Rabael Bhatti |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1215421482 PECOS PAC ID: 8628406501 Enrollment ID: I20200309001688 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Jasmeet K Aujla |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1508487935 PECOS PAC ID: 3577981919 Enrollment ID: I20200916001678 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Roseann Guglielmo |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1730491903 PECOS PAC ID: 8527200013 Enrollment ID: I20201112002879 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Alfredo Mesiti |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1215544895 PECOS PAC ID: 0345651352 Enrollment ID: I20201124000694 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Ramandeep Kaur |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1629685581 PECOS PAC ID: 9234540147 Enrollment ID: I20201125001738 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Thao Hoang Hong Nguyen |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1548850837 PECOS PAC ID: 4587071337 Enrollment ID: I20210629001694 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Bradley Habermehl |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1356375463 PECOS PAC ID: 2365443314 Enrollment ID: I20211025001259 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Mayisha Ahsan-khan |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1518552041 PECOS PAC ID: 6901204379 Enrollment ID: I20211025001314 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Eileen Marie Walsh |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1598731341 PECOS PAC ID: 4082808159 Enrollment ID: I20211026001705 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Christopher O Ogolla |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1366016123 PECOS PAC ID: 4082002738 Enrollment ID: I20211028002309 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Michelle Lynch |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1235786138 PECOS PAC ID: 0749686418 Enrollment ID: I20211104000694 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Justine Mcgeary |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1073286340 PECOS PAC ID: 5890184881 Enrollment ID: I20211112001203 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Al'tiana Manning |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1821615873 PECOS PAC ID: 5092103408 Enrollment ID: I20211117001706 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Karen Mohar Sanghera |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1467884817 PECOS PAC ID: 0446477798 Enrollment ID: I20220104000451 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Deanna Ippolito |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1225683121 PECOS PAC ID: 8426388257 Enrollment ID: I20220111001306 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Amy Keopraseuth |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1265923247 PECOS PAC ID: 7315279270 Enrollment ID: I20220307001251 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | John Wayawotzki |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1063504637 PECOS PAC ID: 1153444989 Enrollment ID: I20220323000801 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Raymond Farmer |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1447823158 PECOS PAC ID: 6002296431 Enrollment ID: I20220701001771 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Jade Liu |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1578208328 PECOS PAC ID: 8426438177 Enrollment ID: I20220712001480 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Joseph Stallone |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1003556762 PECOS PAC ID: 2264813419 Enrollment ID: I20220719001470 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Jeremy Saxon |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1285381897 PECOS PAC ID: 7911388178 Enrollment ID: I20220719001776 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Vincent Andrew Thoren |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1033852330 PECOS PAC ID: 7113309550 Enrollment ID: I20220802002951 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Tabitha Plunske |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1780311514 PECOS PAC ID: 1759765217 Enrollment ID: I20220901000111 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Usama Nasir |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1174257869 PECOS PAC ID: 9335524669 Enrollment ID: I20220922000517 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Liana Marie Ferreira |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1235701160 PECOS PAC ID: 6002219409 Enrollment ID: I20220928000847 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Michael Joyce |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1386992220 PECOS PAC ID: 5395996995 Enrollment ID: I20221010001809 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Lori Rothman |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1326164583 PECOS PAC ID: 1052417003 Enrollment ID: I20221014002148 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Christian Marrero |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1235473968 PECOS PAC ID: 5496999633 Enrollment ID: I20221021001605 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Thuy Nguyen |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1811517899 PECOS PAC ID: 9537567003 Enrollment ID: I20221021002138 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Artis L Beatty |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1972567006 PECOS PAC ID: 6800806092 Enrollment ID: I20221021002279 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Sarah Lung |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1982203683 PECOS PAC ID: 3072924992 Enrollment ID: I20221208002519 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Candace Christen |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1811036056 PECOS PAC ID: 6204886427 Enrollment ID: I20221215000471 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Anika Ramolia |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1205084787 PECOS PAC ID: 0446398945 Enrollment ID: I20221220002522 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Brian Lewy |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1750379087 PECOS PAC ID: 5597089011 Enrollment ID: I20221227001132 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Nayab Davis |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1942782321 PECOS PAC ID: 0547512030 Enrollment ID: I20230213001015 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Jacob Nachum |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1124107685 PECOS PAC ID: 2466587472 Enrollment ID: I20230214001460 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Chinyere Onyenekwu |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1972733293 PECOS PAC ID: 5092990143 Enrollment ID: I20230412001436 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Anusha Bhojani |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1841934833 PECOS PAC ID: 3375900343 Enrollment ID: I20230606003164 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Ogechi Ukegbu |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1750687562 PECOS PAC ID: 4082887674 Enrollment ID: I20230817003550 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Paris Samandi |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1679265854 PECOS PAC ID: 9133582828 Enrollment ID: I20230829000803 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Kathryn Smith-carpenter |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1205232444 PECOS PAC ID: 6002279650 Enrollment ID: I20230829004204 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Tracy Snowden |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1679699680 PECOS PAC ID: 7719020080 Enrollment ID: I20230831004447 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Tiffanie Crisi |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1679199822 PECOS PAC ID: 2668892829 Enrollment ID: I20230928002313 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Lilan Le |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1104230200 PECOS PAC ID: 9032413125 Enrollment ID: I20231027000359 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Provider Name | Rovetta Mattia |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1366497661 PECOS PAC ID: 7416969555 Enrollment ID: I20240216003255 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Myeyedr. 8614 Westwood Center Dr Fl 9, Vienna, VA 22182-2442 Ph: (703) 847-8899 | Myeyedr. 145 Wakelee Ave, Ansonia, CT 06401-1176 Ph: (203) 734-1686 |
News Archive
The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.
A group of 11 genes can successfully predict whether an individual is at increased risk of alcoholism, a research team from the United States and Germany reported Tuesday.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.
› Verified 4 days ago
Dr. Thomas Mitchell Duffy, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 336 Main St, Ansonia, CT 06401 Phone: 203-732-3937 Fax: 203-735-0805 | |
Dr. Usama Nasir, OD Optometrist Medicare: Medicare Enrolled Practice Location: 145 Wakelee Ave, Ansonia, CT 06401 Phone: 203-734-1686 Fax: 203-732-7018 | |
Best Vision Llc Optometrist Medicare: Medicare Enrolled Practice Location: 336 Main St, Ansonia, CT 06401 Phone: 203-732-3937 | |
Kelly T Nguyen, Optometrist Medicare: May Accept Medicare Assignments Practice Location: 336 Main St, Ansonia, CT 06401 Phone: 203-732-3937 Fax: 203-465-1481 |